Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

47.02 +0.30 (+0.64%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,467,902
Open 46.75
Bid (Size) 47.03 (19)
Ask (Size) 47.04 (6)
Prev. Close 46.72
Today's Range 46.60 - 47.15
52wk Range 42.64 - 57.82
Shares Outstanding 1,250,690,553
Dividend Yield 4.05%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers
European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's (NYSE: NVO) popular therapies... 
Via Benzinga
How Is The Market Feeling About Sanofi?
Via Benzinga

Performance

YTD
-4.04%
-4.04%
1 Month
+2.66%
+2.66%
3 Month
-11.18%
-11.18%
6 Month
-7.50%
-7.50%
1 Year
+4.65%
+4.65%

More News

Read More
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
From Teva Pharmaceutical Industries Limited
Via Business Wire
2 Biotech Stocks You Can Buy and Hold for the Next Decade
Via The Motley Fool
Is NASDAQ:SNY a Good Fit for Dividend Investing?
Via Chartmill
Looking Into Sanofi's Recent Short Interest
Via Benzinga
This Stock Just Dropped By 15%: Is It a Buy?
Via The Motley Fool
Teva Pharma is the way to play the re-rise of generic drugs
Via MarketBeat
Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales
Via Investor's Business Daily
Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder
Via Benzinga
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Is NASDAQ:SNY a Good Fit for Dividend Investing?
Via Chartmill
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst
Via Benzinga
US CDC Rolls Out Additional Doses For Sanofi/AstraZeneca Recently Approved Respiratory Infection Drug As Demand Surges
Via Benzinga
Major Buyout Firms Eye Sanofi's Consumer Health Division Spinoff Valued Over $20B
Via Benzinga
Don't overlook NASDAQ:SNY—it's a hidden gem with strong fundamentals and an attractive price tag.
Via Chartmill
MarketBeat Week in Review – 11/6 - 11/10
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Pfizer and Sanofi shares fall, which one to scoop up?
Via MarketBeat
Exposures COVID-19
Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi
Via Investor's Business Daily
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
Via Investor Brand Network
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
Via FinancialNewsMedia
Investor patience tested as pharmaceutical stocks take a tumble
Via MarketBeat
Why Is Gene Therapy Company MeiraGTx Stock Trading Higher Today?
Via Benzinga
Sanofi (SNY) Q3 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.